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dian survival of the subset of patients with stage IIIB locoregional (LR) 
disease. The results for this subgroup are now available and are reported 
here together with the updated survival for the overall population. 
Method: 171 patients with ECOG 0-2 stage IIIB/IV NSCLC that had 
stable or responding disease after any ﬁrst-line chemotherapy (CT) 
with or without radiotherapy were randomized 1:1 to receive either L-
BLP25 plus best supportive care (BSC) or BSC alone. Randomization 
was stratiﬁed by stage of disease (IIIB LR or stage IIIB with malignant 
pleural effusion and stage IV). Patients in the L-BLP25 arm received a 
single i.v. dose of cyclophosphamide 300mg/m2 followed by 8 weekly 
sc immunizations with L-BLP25 (1000μg). Subsequent immunizations 
were administered at 6-wk intervals. An analysis of 65 patients with 
stage IIIB LR disease was conducted, and the results are shown in the 
table below together with the updated 3 year survival for the overall 
population. 
Results: 
 Overall Population Stage IIIB subgroup
 BSC L-BLP25 + BSC Total BSC
L-BLP25 + 
BSC Total
N 83 88 171 30 35 64
Median 
follow up 
(mths)
56 51 52 57 53 53
Median 
Survival 
(mths)
13.0 17.2 p=0.085* 13.3 30.6 p=NS**
95% CI 11.2, 16.2 12.9, 24.2  9.6, 28.1 13.4, -  
Hazard 
Ratio   0.75   0.55
95% CI   0.53, 1.04   0.30, 1.00
1 yr OS 46 (55) 55 (63)  17 (57) 24 (69)  
2 yr OS 22 (27) 36 (41)  10 (33) 20 (57)  
3 yr OS 14 (17) 27 (31)  8 (27) 17 (49)  
* P-value; adjusted for multiple comparisons. Unadjusted p-values for this subgroup based on a Cox 
model including response to ﬁrst-line treatment; 0.0497
**P-value of the primary analysis (March 2004) was p=0.112 
Conclusion: A 17.3 month difference in median survival and 45% 
reduction in mortality were seen with maintenance therapy with 
L-BLP25 in patients with stage IIIB LR NSCLC. The difference in 
efﬁcacy identiﬁed in this subgroup versus patients with IIIB MPE or 
stage IV disease, could potentially be a result of lower tumor burden 
or less advanced disease. On the basis of these results, a phase III trial 
(“START”) has been initiated to investigate the addition of mainte-
nance therapy with L-BLP25 to BSC in patients with unresectable stage 
III NSCLC. 
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Background: The clusterin gene is frequently expressed in NSCLC 
and encodes a cytoprotective chaperone protein that is upregulated in 
response to apoptotic stimuli such as chemotherapy. OGX-011 is a sec-
ond-generation antisense oligonucleotide that inhibits clusterin expres-
sion, thus enhancing the apoptotic effects of chemotherapy. Previous 
phase I studies with docetaxel suggested an OGX-011 dose of 640mg 
was feasible and biologically active; therefore, the current study began 
with a run-in phase with 480mg of OGX-011.
Methods: Eligibility criteria: stage IIIB/IV NSCLC; no prior chemo-
therapy; ≥ 1 measurable lesion; ECOG ≤1; adequate organ function; no 
active CNS metastasis. Treatment: OGX-011 is given as a 2-hour infu-
sion. There is an initial loading phase with 3 doses of OGX-011 alone 
in 1 week, followed by weekly OGX-011 with standard chemotherapy: 
gemcitabine (1250 mg/m2) Days 1+8 and either cisplatin (75 mg/m2) or 
carboplatin (AUC=5) Day 1 q21 days, (maximum 6 cycles).
Results: 85 pts (phase 1=10 and phase 2=75) were enrolled between 
Dec, 2004 and Nov, 2006. As no unexpected dose limiting toxicities 
were noted in the ﬁrst 3 patients who received 480mg of OGX-011, the 
dose was escalated, as planned, to 640 mg for the remaining patients. 
Data are available on the ﬁrst 53 pts; all received ≥1 dose of OGX-011 
and were considered evaluable for safety and efﬁcacy. Demographics: 
female (47%); stage IV (87%); median age 61 (45-79) yrs; ECOG PS = 
1 (62%). The median number of cycles delivered was 4. Principal grade 
3/4 toxicities were hematologic: neutropenia (32%) + thrombocytope-
nia (17%). Other common toxicities included fatigue, nausea, vomiting, 
fever, chills, constipation, + anorexia. Two Serious Adverse Events 
previously reported as associated with gemcitabine/platinum therapy 
were documented: acute cortical blindness with stroke + thrombotic 
thrombocytopenic purpura. Responses: conﬁrmed PRs 13 (ORR = 
24%); median duration of PR: 105 days (46-336+); median PFS: 140 
days (2-422+); 79% of pts have progressed; 47% have died. Of the 
ﬁrst 34 patients who have all been followed for ≥ 1 yr, 18/34 (53%) 
survived > 1 yr; 14/18 (78%) remain alive as of March 06, 2006. Data 
will be presented for all 85 patients.
Conclusions: This combination is feasible and tolerable. The 1-yr 
survival rate ≥50% may justify a randomized phase III trial. OGX-011 
is being developed by OncoGenex Technology Inc. + Isis Pharmaceu-
ticals Inc.
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Background: Angiogenesis, the formation of new blood vessels, is 
an essential process during growth and progression of different solid 
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tumors. Vascular endothelial growth factor (VEGF) induces vascular 
permeability and plays a major role in vasculogenesis, angiogenesis, 
and endothelial integrity and survival. Besides VEGF-, other proangio-
genic factors such as platelet derived- (PDGF), and ﬁbroblast growth 
factor (FGF) with their receptors compose critical cellular pathways 
controlling lung cancer vascularization, growth and progression. BIBF 
1120 is an oral potent triple angiokinase inhibitor targeting VEGFR, 
PDGFR, FGFR kinases.
Methods: In this double blind multi-centre trial, patients with an 
ECOG score of 0-2 with locally advanced or metastatic (stage IIIB/IV) 
relapsed NSCLC after failure of ﬁrst or second line chemotherapy were 
randomly assigned to daily treatment with 2x250 mg or 2x150 mg of 
BIBF 1120 until progression. In the event of dose limiting toxicity, a 
single dose reduction to open label treatment with 2x150 or 2x100 mg 
of BIBF 1120 was allowed. Patients with stable brain metastases or 
squamous cell carcinoma were not excluded. The primary endpoints 
were progression free survival (PFS) and objective tumour response 
according to RECIST (determined every 6 weeks).
Results: A total of 74 patients were enrolled and 73 patients treated 
with BIBF 1120 (61% males, median age: 64 years, range 36-80). The 
most common histology was adenocarcinoma (55%), followed by squa-
mous cell carcinoma (23%). The median PFS of all patients (n= 73) 
was 1.6 months without signiﬁcant difference between both treatment 
arms. The stable disease rate was 48%. One conﬁrmed partial response 
was observed. 
Patients with an ECOG performance status of 0 or 1 (n= 57) had a me-
dian PFS of 2.9 months and a three- and ﬁve months PFS rate of 46% 
and 31%, without any difference between both treatment arms. The 
stable disease rate in this group of patients was 59% and the median 
overall survival was 144 days.
Patients treated with 2x250 mg per day had more CTCAE Grade 3 
and 4 toxicities as compared to patients treated with 2x150 mg (27% 
versus 2.8%, p=0.006, two-sided Fisher-test). The most frequent 
adverse events irrespective of relatedness observed in 73 patients were 
of CTCAE Grade 1 or 2 and included nausea (41%), diarrhoea (41%), 
vomiting (33%), fatigue (29%), and abdominal pain (22%). Grade 3 
and 4 toxicities included nausea (8%), diarrhoea (7%), vomiting (4%), 
abdominal pain (4%) and AST and/or ALT elevations (5.4%) which 
were fully reversible.
Conclusions: These results suggest that continuous treatment with 
BIBF 1120 is safe and well tolerated, and showed promising efﬁcacy in 
ECOG 0-1 patients. A considerably high rate of disease control could 
be observed in this study.
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Background: DN-101 is a high dose oral formulation of calcitriol, the 
most potent ligand of vitamin D receptor. Calcitriol has various anti-
neoplastic effects on malignant cells and increases activity of cytotoxic 
agents, including taxanes. DN-101 in combination with docetaxel 
increased survival in a phase 2 study in androgen-independent prostate 
cancer and ASCENT 2, a phase 3 conﬁrmatory study is underway. The 
objective of the study was to determine the maximum tolerated dose, 
response rate (ORR), progression-free survival (PFS), and overall 
survival (OS) of DN-101 in combination with docetaxel in advanced 
NSCLC patients (pts). 
Methods: Eligible pts had Stage IIIB or IV NSCLC that progressed 
on or after platinum-based chemotherapy, ECOG ≤ 1, and measurable 
disease by RECIST criteria. DN-101 was administered on day 1 in 
doses of 45 (n=5), 75 (n=4), 135 (n=3), or 180 µg (n=53) in the q21d 
group, or 180 µg on day 1, followed by 45 (n=5), 90 (n=4), or 180 µg 
(n=12) on days 8 and 15 in the q7d group. Docetaxel (75 mg/m2 BSA) 
was given on day 2 q21d for all pts. 
Results: A total of 86 pts were treated. No unexpected toxicities were 
reported with DN-101. Grade (G3/4) toxicities and fatal adverse events 
(AEs) were consistent with the reported toxicity of docetaxel alone. 
Stomatitis (0% in q7d, 9% in q21d) and G3/4 asthenia and fatigue 
(5% in q7d, 14% in q21d) were less frequent on DN-101 compared to 
published reports on docetaxel. No pt on DN-101 q21d developed hy-
percalcemia while 2 pt on DN-101 q7d (180 µg cohort) developed G3/4 
hypercalcemia. Three fatal AEs included 2 on DN-101 q21d (1 lung 
inﬁltration, 1 pneumonitis) and 1 on DN-101 q7d (intestinal perfora-
tion). The ORR was 5.9% (CI 0.1%, 28.7%) and 6.6% (1.8%, 15.9%), 
median PFS 14.1 (6.0, 20.0) and 11.6 (8.4, 17.4) weeks, median OS 
8.8 (7.1, NA) and 6.9 (5.5, 9.7) months, and 1 year survival rate 40% 
(15.2%, 64.8%) and 31% (18.9%, 42.2%) for the q7d and q21d group, 
respectively. 
Conclusion: DN-101 in combination with docetaxel is well-tolerated 
in advanced NSCLC. The observation of improved PFS, OS, and 1 
year survival rate with weekly DN 101 supports further investigation, 
as does the appearance of ameliorated docetaxel-induced toxicity when 
combined with DN-101. 
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Background: NSCLC is associated with poor outcome: even after 
complete surgical resection, about half of the patients with stage IB or 
II NSCLC relapse and die within 5 years. Cisplatin-based adjuvant che-
